Abdullah Zaawari*

Intern, Clinical Pharmacy Department, KIMS Hospital, Secunderabad, India

*Corresponding Author: Abdullah Zaawari, Intern, Clinical Pharmacy Department, Kims Hospital, Secunderabad, India.

Received: November 15, 2021; Published: November 30, 2021

Abstract

It has been less than two centuries since the discovery of hydrochloric acid in the stomach. The understanding of the molecular pathways enabled efficient therapeutic reduction of stomach acid secretion. The remarkable advancements in the treatment of acid-related illnesses are the result of the combined efforts of several excellent pharmacologists, basic scientists, and clinical physicians. Effective stomach acid suppression therapy has significantly improved acid-related disorder treatment and prognosis. The use of proton pump inhibitors (PPIs) in clinical practice has revolutionized the medical treatment of upper gastrointestinal disorders dramatically. PPIs are the "gold standard" treatment for acid-related disorders. However, several issues persist in the treatment of acid-related disorders, such as the management of patients who do not respond adequately to PPI therapy, more effective gastroprotection, or more potent antisecretory treatment for the eradication of Helicobacter pylori infection. New ant secretory medications are continuously being developed and investigated to give a more effective and profound inhibition of stomach acid secretion. The development of acid pump antagonists, or potassium channel acid-blocking drugs (P-CABs), has been a significant step ahead.

Keywords: Gastric Acid Suppression; H2-receptor Blocker; Proton Pump Inhibitor; Potassium-competitive acid Blocker; Acid-related Disorder; Helicobacter pylori; Gastroesophageal Reflux Disease; Gastroprotection; Safety

References

1. Modlin, I M. “From Prout to the proton pump-a history of the science of gastric acid secretion and the surgery of peptic ulcer”. Surgery, Gynecology and Obstetrics1 (1990): 81-96.
2. Schmidt PT., et al. “Tachykinins Stimulate Acid and Pepsinogen Secretion in the Isolated Porcine Stomach”. Acta Physiologica Scandinavica4 (1999): 335-340.
3. Herszényi Lászlo., et al. “Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future”. Digestive Diseases2 (2019): 104-111.
4. Prout WG., et al. “On the nature of the acid and saline matters usually existing in the stomachs of animals”. Gut 15 (1974): 45-49.
5. Banić M., et al. “Historical impact to drive research in peptic ulcer disease”. Digestive diseases 5 (2011): 444-453.
6. Konturek SJ., et al. “From nerves and hormones to bacteria in the stomach; Nobel prize for achievements in gastrology during last century”. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society4 (2005): 507-530.
7. Herszényi László., et al. “A fekélybetegség és a stressz” [Peptic ulcer disease and stress]. Orvosi hetilap35 (2015): 1426-1429.
8. Gaynor Erin C and Christine M Szymanski. “The 30th Anniversary of Campylobacter, Helicobacter, and Related Organisms Workshops-What Have We Learned in Three Decades?” Frontiers in Cellular and Infection Microbiology 2 (2012).
9. Graham David Y. “History of Helicobacter pylori, duodenal ulcer, gastric ulcer, and gastric cancer”. World Journal of Gastroenterology18 (2014): 5191-5204.
10. Engevik Amy C., et al. “The Physiology of the Gastric Parietal Cell”. Physiological Reviews2 (2020): 573-602.
11. Li Yifei., et al. “Chronic Atrophic Gastritis: A Review”. Journal of environmental pathology, toxicology, and oncology: official organ of the International Society for Environmental Toxicology and Cancer3 (2018): 241-259.
12. Hain Elisabeth., et al. “Prise en charge du gastrinome [Management of gastrinoma]”. Presse Medicale (Paris, France: 1983)11 (2016): 986-991.
13. Huang JQ and RH Hunt. “Pharmacological and pharmacodynamic essentials of H (2)-receptor antagonists and proton pump inhibitors for the practicing physician”. Best Practice and Research. Clinical Gastroenterology3 (2001): 355-370.
14. Shim Young Kwang and Nayoung Kim. “The Effect of H₂Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy”. The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi1 (2017): 4-12.
15. Tutuian, Radu., et al. “Nocturnal acid breakthrough: pH, drugs, and bugs”. European Journal of Gastroenterology and Hepatology5 (2004): 441-443.
16. Hersey SJ and G Sachs. “Gastric acid secretion”. Physiological reviews1 (1995): 155-189.
17. Sachs G., et al. “The pharmacology of the gastric acid pump: the H+, K+ ATPase”. Annual Review of Pharmacology and Toxicology 35 (1995): 277-305.
18. Aihara Takeshi., et al. “Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future”. Pharmacology and Therapeutics1 (2003): 109-127.
19. Garnett William R. “History of acid suppression: focus on the hospital setting”. Pharmacotherapy10-2 (2003): 56S-60S.
20. Scarpignato Carmelo., et al. “Acid suppression therapy: where do we go from here?”. Digestive Diseases (Basel, Switzerland)1-2 (2006): 11-46.
21. Herszényi L and Z Tulassay. “A protonpumpagátlók összehasonlító vizsgálata” [Comparative study of proton pump inhibitors]. Orvosi Hetilap36 (2001): 1953-1961.
22. Hagymási Krisztina., et al. “Update on the pharmacogenomics of proton pump inhibitors”. Pharmacogenomics6 (2011): 873-888.
23. Scarpignato Carmelo., et al. “Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression”. BMC Medicine1 (2006) 179.
24. Yadlapati Rena and Peter J Kahrilas. “When is proton pump inhibitor use appropriate?”. BMC Medicine1 (2017): 36.
25. Freedberg Daniel E., et al. “The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice from the American Gastroenterological Association”. Gastroenterology4 (2017): 706-715.
26. Moayyedi Paul., et al. “Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin”. Gastroenterology3 (2019): 682-691.
27. Scarpignato Carmelo and Richard H Hunt. “Proton pump inhibitors: the beginning of the end of the end of the beginning?”. Current Opinion in Pharmacology6 (2008): 677-684.
28. DeVault Kenneth R and Nicholas J Talley. “Insights into the future of gastric acid suppression”. Nature reviews. Gastroenterology and Hepatology9 (2009): 524-532.
29. Maradey-Romero Carla and Ronnie Fass. “New and future drug development for gastroesophageal reflux disease”. Journal of Neurogastroenterology and Motility1 (2014): 6-16.
30. Garnock-Jones Karly P. “Vonoprazan: first global approval”. Drugs4 (2015): 439-443.
31. Echizen Hirotoshi. “The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations”. Clinical Pharmacokinetics4 (2016): 409-418.
32. Hunt Richard H and Carmelo Scarpignato. “Potent Acid Suppression with PPIs and P-CABs: What's New?”. Current Treatment Options in Gastroenterology4 (2018): 570-590.
33. Scarpignato Carmelo and Richard H Hunt. “The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease”. Current Opinion in Gastroenterology4 (2019): 344-355.
34. Xiao Yinglian., et al. “Phase III, randomized, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis”. Gut2 (2020): 224-230.
35. Miwa Hiroto., et al. “Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease”. Journal of Gastroenterology8 (2019): 718-729.
36. Miyazaki Hirota., et al. “Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review”. Journal of Gastroenterology and Hepatology8 (2019): 1316-1328.
37. Kawai Takashi., et al. “Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomized phase 3 study”. Gut6 (2018): 1033-1041.
38. Jung YS., et al. “Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication”. Alimentary Pharmacology and Therapeutics2 (2017): 106-114.
39. Furuta Takahisa., et al. “Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori”. Digestion6 (2020): 743-751.
40. O'Connor Anthony., et al. “Review: Treatment of Helicobacter pylori Infection 2019”. Helicobacter1 (2019): e12640.

Citation

Citation: Abdullah Zaawari. “Pharmacology of Gastric Acid Suppression and Regulation: Past, Present, and Future". Acta Scientific Pharmacology 2.12 (2021): 20-26.

Copyright

Copyright: © 2021 Abdullah Zaawari. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.